AstraZeneca plc vs Global X Defense Tech ETF — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Global X Defense Tech ETF trades at $70.17. The key difference: AstraZeneca plc pays a 2.01% dividend while Global X Defense Tech ETF pays none, and Global X Defense Tech ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | SHLD | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $209.48 | $78.02 |
52-Week Low | $147.06 | $58.20 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
SHLD, the Global X Defense Tech ETF, trades at $70.08, up 0.33% with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights institutional accumulation, including Focus Financial Network increasing its stake by 55.4% in Q2 2026 (Defense World, 2026-08-11). The ETF provides diversified exposure to global defense stocks amid rising military spending trends.
Outlook is supported by geopolitical tensions and defense budget growth, but risks include policy shifts and valuation concerns. Analysts note SHLD's lower fees and tech focus versus peers, with a dividend of $0.19 scheduled for July 2026. Key resistance is at $70, with support at $69.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →